Abstract | AIM: METHODS AND RESULTS: The primary outcome was the composite of a worsening heart failure event (urgent clinic visit, emergency department visit, or hospitalization) or cardiovascular death. We prespecified analysis of the effect of treatment according to baseline NT-proBNP (≤ median, > median), excluding individuals with atrial fibrillation/flutter (AF/AFL). Of the 8232 patients analysed, 8206 had an available baseline NT-proBNP measurement. Among the 5971 patients not in AF/AFL, the median (Q1-Q3) NT-proBNP level was 1675 (812-3579) pg/ml. Hazard ratios (HR) for the effect of omecamtiv mecarbil, compared with placebo, for the primary endpoint in patients without AF/AFL were: ≤ median 0.94 (95% confidence interval [CI] 0.80-1.09), > median 0.81 (0.73-0.90) (p-interaction = 0.095); for the overall population (including patients with AF/AFL) the HRs were ≤ median 1.01 (0.90-1.15) and > median 0.88 (0.80-0.96) (p-interaction = 0.035). There was an interaction between treatment and NT-proBNP, examined as a continuous variable, with greater effect of omecamtiv mecarbil on the primary outcome in patients with a higher baseline NT-proBNP (p-interaction = 0.086). CONCLUSIONS: In GALACTIC-HF, the benefit of omecamtiv mecarbil appeared to be larger in patients with higher baseline NT-proBNP levels, especially in patients without AF/AFL. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT02929329; EudraCT number, 2016-002299-28.
|
Authors | Kieran F Docherty, John J V McMurray, Brian L Claggett, Zi Michael Miao, Kirkwood F Adams, Alexandra Arias-Mendoza, John G F Cleland, Rafael Diaz, Luis E Echeverria Correa, G Michael Felker, Candida Fonseca, Jing Li, Marco Metra, Karen Sliwa-Hahnle, Scott D Solomon, Hans J Vandekerckhove, Dragos Vinereanu, Adriaan A Voors, Stephen B Heitner, Stuart Kupfer, Fady I Malik, Lisa Meng, John R Teerlink |
Journal | European journal of heart failure
(Eur J Heart Fail)
Vol. 25
Issue 2
Pg. 248-259
(02 2023)
ISSN: 1879-0844 [Electronic] England |
PMID | 36597719
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2023 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. |
Chemical References |
- Biomarkers
- Natriuretic Peptide, Brain
- omecamtiv mecarbil
- Peptide Fragments
- pro-brain natriuretic peptide (1-76)
|
Topics |
- Humans
- Atrial Fibrillation
- Biomarkers
- Heart Failure
- Natriuretic Peptide, Brain
(therapeutic use)
- Peptide Fragments
(therapeutic use)
- Prognosis
- Stroke Volume
(physiology)
|